These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23275776)

  • 1. Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor.
    Devata S; Kim EJ
    Case Rep Oncol; 2012 Sep; 5(3):622-6. PubMed ID: 23275776
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors.
    Squires MH; Worth PJ; Konda B; Shah MH; Dillhoff ME; Abdel-Misih S; Norton JA; Visser BC; Dua M; Pawlik TM; Schmidt CR; Poultsides G; Cloyd JM
    Pancreas; 2020 Mar; 49(3):355-360. PubMed ID: 32132509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A retrospective study of capecitabine/temozolomide (CAPTEM) regimen in the treatment of metastatic pancreatic neuroendocrine tumors (pNETs) after failing previous therapy.
    Saif MW; Kaley K; Brennan M; Garcon MC; Rodriguez G; Rodriguez T
    JOP; 2013 Sep; 14(5):498-501. PubMed ID: 24018594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic neuroendocrine tumors: does chemotherapy work?
    Tejani MA; Saif MW
    JOP; 2014 Mar; 15(2):132-4. PubMed ID: 24618436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Efficacy of the S-1/Temozolomide Regimen in Patients with Metastatic Neuroendocrine Tumors.
    Zhao J; Zhao H; Chi Y
    Neuroendocrinology; 2018; 106(4):318-323. PubMed ID: 28817826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
    Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
    Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
    Mujica-Mota R; Varley-Campbell J; Tikhonova I; Cooper C; Griffin E; Haasova M; Peters J; Lucherini S; Talens-Bou J; Long L; Sherriff D; Napier M; Ramage J; Hoyle M
    Health Technol Assess; 2018 Sep; 22(49):1-326. PubMed ID: 30209002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic treatment of neuroendocrine tumors with hepatic metastases.
    Demirkan BH; Eriksson B
    Turk J Gastroenterol; 2012; 23(5):427-37. PubMed ID: 23161287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs).
    Strosberg J
    Gastrointest Cancer Res; 2013 Jul; 6(4 Suppl 1):S10-2. PubMed ID: 24312683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emerging therapies and latest development in the treatment of unresectable pancreatic neuroendocrine tumors: an update for clinicians.
    Sharma J; Duque M; Saif MW
    Therap Adv Gastroenterol; 2013 Nov; 6(6):474-90. PubMed ID: 24179483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pancreatic neuroendocrine tumors: A review of serum biomarkers, staging, and management.
    Ma ZY; Gong YF; Zhuang HK; Zhou ZX; Huang SZ; Zou YP; Huang BW; Sun ZH; Zhang CZ; Tang YQ; Hou BH
    World J Gastroenterol; 2020 May; 26(19):2305-2322. PubMed ID: 32476795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
    Crespo G; Jiménez-Fonseca P; Custodio A; López C; Carmona-Bayonas A; Alonso V; Navarro M; Aller J; Sevilla I; Grande E; Gajate P; Alonso-Gordoa T; Matos I; Capdevila J; Nieto B; Barriuso J
    Future Oncol; 2017 Mar; 13(7):615-624. PubMed ID: 27802780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of well-differentiated neuroendocrine tumors.
    Tella SH; Starr JS; Kommalapati A; Sonbol MB; Halfdanarson TR
    Clin Adv Hematol Oncol; 2021 Sep; 19(9):582-593. PubMed ID: 34495022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic neuroendocrine tumors: approach to treatment with focus on sunitinib.
    Vinik AI; Raymond E
    Therap Adv Gastroenterol; 2013 Sep; 6(5):396-411. PubMed ID: 24003340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy.
    Claringbold PG; Turner JH
    Neuroendocrinology; 2016; 103(5):432-9. PubMed ID: 26065489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.
    Strosberg JR; Fine RL; Choi J; Nasir A; Coppola D; Chen DT; Helm J; Kvols L
    Cancer; 2011 Jan; 117(2):268-75. PubMed ID: 20824724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.
    Ramirez RA; Beyer DT; Chauhan A; Boudreaux JP; Wang YZ; Woltering EA
    Oncologist; 2016 Jun; 21(6):671-5. PubMed ID: 27226359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capecitabine and Temozolomide in Patients with Advanced Pulmonary Carcinoid Tumours.
    Papaxoinis G; Kordatou Z; McCallum L; Nasralla M; Lamarca A; Backen A; Nonaka D; Mansoor W
    Neuroendocrinology; 2020; 110(5):413-421. PubMed ID: 31437838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent Updates in the Management of Advanced Pancreatic Neuroendocrine Tumors.
    Cho CM
    Korean J Gastroenterol; 2019 Mar; 73(3):124-131. PubMed ID: 31013555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.